Is a
Clinical Study attributes
NCT Number
Trial Recruitment Size
490
Trial Sponsor
Clinical Trial Start Date
2006
0Primary Completion Date
2008
0Study Completion Date
2008
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Biological0
Interventional Trial Phase
Phase 30
Official Name
A Phase III Open-Label, Prospective, Multicenter Study of the Efficacy, Tolerability, Safety, and Pharmacokinetics of Immune Globulin Subcutaneous (Human), IgPro20 in Subjects With Primary Immunodeficiency (PID)0
Last Updated
January 25, 2013
0Allocation Type
NA0
Intervention Model
Single Group Assignment0
Masking Type
None (Open Label)0
Other attributes
Intervention Treatment
Human Normal Immunoglobulin for Subcutaneous Administration0
Study summary
The objective of this study is to assess the efficacy, tolerability, safety and pharmacokinetics of IgPro20 in patients with primary humoral immunodeficiency (PID).
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
